Litcius/Paper detail

A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy

Pezhman Shiri, Sorour Ramezanpour, Ali Mohammad Amani, Wim Dehaen

2022Molecular Diversity58 citationsDOI

Topics & Concepts

RegorafenibPazopanibLenvatinibAngiogenesisTyrosine kinaseCancer researchMedicinePharmacologyReceptor tyrosine kinaseSorafenibKinaseCancerSunitinibInternal medicineChemistryReceptorColorectal cancerBiochemistryHepatocellular carcinomaChemical Reactions and IsotopesScience, Research, and MedicineAdvanced Breast Cancer Therapies